Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: Single centre retrospective analysis

Mycoses

Volumn 58, Issue 7, 2015, Pages 432-436

  Miceli, Marisa H ^a   Perissinotti, Anthony J ^b   Kauffman, Carol A ^a,c   Couriel, Daniel R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

Antifungals; Posaconazole tablets; Therapeutic drug monitoring

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; POSACONAZOLE; PROTON PUMP INHIBITOR; ANTIFUNGAL AGENT; DELAYED RELEASE FORMULATION; TABLET; TRIAZOLE DERIVATIVE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CANCER PATIENT; CLINICAL ARTICLE; DIARRHEA; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; TABLET FORMULATION; BIOAVAILABILITY; BLOOD; COMPLICATION; DELAYED RELEASE FORMULATION; HEMATOLOGIC DISEASE; MIDDLE AGED; MYCOSES; ORAL DRUG ADMINISTRATION; TABLET; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; BODY MASS INDEX; BODY WEIGHT; DELAYED-ACTION PREPARATIONS; DIARRHEA; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MYCOSES; RETROSPECTIVE STUDIES; TABLETS; TRIAZOLES; YOUNG ADULT;

EID: 84937190960     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12339     Document Type: Article

References (19)

1. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-17.
2. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999; 28: 331-40.
3. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. New Engl J Med 2007; 356:348-59.
4. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. New Engl J Med 2007; 356: 335-47.
5. Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother 2012; 56: 5503-10.
6. Krishna G, Ma L, Martinho M, Preston RA, O'Mara E. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother 2012; 67: 2725-30.
7. FDA. FDA approves Posaconazole delayed release tablets, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205053s000lbl.pdf [Accessed 2014 October 12, 2014].
8. Duarte RF, Lopez-Jimenez J, Cornely OA, Laverdiere M, Helfgott D, Haider S, et al. Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrob Agents Chemother 2014; 58: 5758-65.
9. Dolton MJ, Ray JE, Marriott D, McLachlan AJ. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother 2012; 56: 2806-13.
10. Jang SH, Colangelo PM, Gobburu JVS. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 2010; 88: 115-9.
11. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. http://www.evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:5x7.pdf [Accessed on 26 February 2015].
12. Tonini J, Thiebaut A, Jourdil JF, Berruyer AS, Bulabois CE, Cahn JY, et al. Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease. Antimicrob Agents Chemother 2012; 56: 5247-52.
13. Eiden C, Meniane JC, Peyriere H, Eymard-Duvernay S, Le Falher G, Ceballos P, et al. Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake. Eur J Clin Microbiol Infect Dis 2012; 31: 161-7.
14. Gross BN, Ihorst G, Jung M, Wasch R, Engelhardt M. Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature. Pharmacotherapy 2013; 33: 1117-25.
15. World Health Organization. Obesity and overweight. http://www.who.int/mediacentre/factsheets/fs311/en [Accessed on 26 February 2015].
16. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49: 71-87.
17. Wurtz R, Itokazu G, Rodvold K. Antimicrobial dosing in obese patients. Clin Infect Dis 1997; 25: 112-8.
18. Li Y, Theuretzbacher U, Clancy CJ, Nguyen MH, Derendorf H. Pharmacokinetic/ pharmacodynamic profile of posaconazole. Clin Pharmacokinet 2010; 49: 379-96.
19. Felton T, Troke PF, Hope WW. Tissue penetration of antifungal agents. Clin Microbiol Rev 2014; 27: 68-88.